» Articles » PMID: 27474493

Plant-produced Crimean-Congo Haemorrhagic Fever Virus Nucleoprotein for Use in Indirect ELISA

Overview
Journal J Virol Methods
Specialty Microbiology
Date 2016 Jul 31
PMID 27474493
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Crimean-Congo haemorrhagic fever (CCHF) is a disease of serious public concern caused by the CCHF virus (CCHFV). Anti-CCHFV IgG in humans can be detected using ELISA with native antigen prepared from cell cultures which have been infected with virus or from brain tissue of suckling mice which have been inoculated with virus. However, the preparation of these reagents requires high biosafety levels and is expensive. A safer, more cost-effective recombinantly-produced NP reagent is desirable. Recently, plants have been shown to be a cost-effective and safe system for expression of recombinant proteins. This work describes cloning of the CCHFV NP gene into three different plant expression systems and comparison of expression in Nicotiana benthamiana. The highest expressing construct was selected. Expressed NP was purified by ammonium sulphate fractionation prior to histidine affinity chromatography. Purified NP was tested in an indirect ELISA to determine if the recombinant antigen was able to detect anti-CCHFV IgG in sera from convalescent patients. Plant-produced NP detected IgG antibodies against CCHFV in 13/13 serum samples from convalescent patients and 0/13 samples collected from volunteers with no history of CCHFV infection. Results were compared with commercially available immunofluorescent assays and 100% concordance was obtained between the two assays. This suggests that a full evaluation of the plant produced NP for application as a safe recombinant is warranted.

Citing Articles

The Role of Nucleocapsid Protein (NP) in the Immunology of Crimean-Congo Hemorrhagic Fever Virus (CCHFV).

Pirincal A, Doymaz M Viruses. 2024; 16(10).

PMID: 39459881 PMC: 11512346. DOI: 10.3390/v16101547.


Nucleocapsid protein-specific monoclonal antibodies protect mice against Crimean-Congo hemorrhagic fever virus.

Garrison A, Moresco V, Zeng X, Cline C, Ward M, Ricks K Nat Commun. 2024; 15(1):1722.

PMID: 38409240 PMC: 10897337. DOI: 10.1038/s41467-024-46110-4.


Mapping of Antibody Epitopes on the Crimean-Congo Hemorrhagic Fever Virus Nucleoprotein.

Lombe B, Saito T, Miyamoto H, Mori-Kajihara A, Kajihara M, Saijo M Viruses. 2022; 14(3).

PMID: 35336951 PMC: 8955205. DOI: 10.3390/v14030544.


Integrating plant molecular farming and materials research for next-generation vaccines.

Chung Y, Church D, Koellhoffer E, Osota E, Shukla S, Rybicki E Nat Rev Mater. 2021; 7(5):372-388.

PMID: 34900343 PMC: 8647509. DOI: 10.1038/s41578-021-00399-5.


Immune responses in multiple hosts to Nucleocapsid Protein (NP) of Crimean-Congo Hemorrhagic Fever Virus (CCHFV).

Karaaslan E, Cetin N, Kalkan-Yazici M, Hasanoglu S, Karakecili F, Ozdarendeli A PLoS Negl Trop Dis. 2021; 15(12):e0009973.

PMID: 34851958 PMC: 8635347. DOI: 10.1371/journal.pntd.0009973.